Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004225 · ClinicalTrials.gov registry record · Phase 1
Gene Therapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00004225: Completed Phase 1 study, sponsored by Eastern Cooperative Oncology Group.
NCT00004225 is a Phase 1 study that has completed, run by Eastern Cooperative Oncology Group. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004225, a Phase 1 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Inserting the gene for p53 into a person's cancer cells may improve the body's ability to fight cancer. Radiation therapy uses high-energy x-rays to damage tumor cells. PURPOSE: Phase I trial to study the effectiveness of gene therapy plus radiation therapy in treating patients who have non-small cell lung cancer.
Interventions
- RADIATION radiation therapy
- BIOLOGICAL Ad5CMV-p53 gene
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-01 |
| Phase | Phase 1 |
What the finished NCT00004225 record still lists
NCT00004225 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which radiation therapy is the first listed.
NCT00004225 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00004225 about?
NCT00004225 is a clinical study titled "Gene Therapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer". RATIONALE: Inserting the gene for p53 into a person's cancer cells may improve the body's ability to fight cancer. Radiation therapy uses high-energy x-rays to damage tumor cells. PURPOSE: Phase I trial to study the effectiveness of gene therapy plus radiation therapy in treating patients who have ...
What is the current status of trial NCT00004225?
This trial is currently completed. It is a Phase 1 study. The study started on 2000-01.
What interventions are being tested in trial NCT00004225?
The interventions under investigation include: radiation therapy (RADIATION), Ad5CMV-p53 gene (BIOLOGICAL).
Who is sponsoring clinical trial NCT00004225?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia